Haisco(SZ:002653)2024-09-20 10:12Financial Performance - The company achieved a revenue of 16.86 billion CNY in the first half of 2024, representing a year-on-year growth of 23.14% [1] - The net profit attributable to shareholders reached 1.64 billion CNY, with a significant increase of 119.40% compared to the previous year [1] - The operating income for the pharmaceutical manufacturing industry in China decreased by 0.9% in the first half of 2024, while the company's revenue grew [3] Product Development and Innovation - The company launched two Class 1 innovative drugs in the first half of 2024: Simenine® and Beichangping® [1] - HSK21542, targeting postoperative pain relief, is expected to be approved for market release in the first half of 2025 [1] - HSK31858 (DPP-1) is set to enter Phase III clinical trials in China within 2024, having been designated as a breakthrough therapy [1] Market Expansion and Sales - The company’s innovative drug Beichangping® was approved for sale in June 2024, with approximately 800 hospitals and pharmacies currently selling it, projecting sales of several million CNY for the year [2] - The company is actively preparing for national medical insurance negotiations to include two newly launched products in the national medical insurance catalog [2] Research and Development Capabilities - The company has over 800 personnel in its R&D team, covering the entire drug development chain from drug screening to clinical trials [3] - The company employs advanced technologies, including AI, to enhance drug screening processes and improve success rates [4] - The company has a robust clinical team of over 400 members, ensuring effective management throughout the clinical drug development process [3]